Patient self-report tool on side effects in cancer clinical trials validated by landmark study
the ONA take:
A landmark study has validated the National Cancer Institute’s Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) as an accurate, reliable, and responsive measure of side effects experienced by patients participating in clinical trials. This study compared the PRO-CTCAE with other patient-reported and clinical measures.
More than 1,000 patients from clinical practices across the United States, including seven cancer centers, were recruited to participate in the study.
They were asked to complete the PRO-CTCAE before appointments. Their reports were compared against other established measures of symptoms such as case and quality of life reports and prescription information.
The researchers validated 119 of 125 PRO-CTCAE questions against the established measurement tools usually based on information from providers. Underrepresentation in the study population prohibited evaluation of the five questions that could not be validated.
This study was unique in that more than 100 distinct questions about symptomatic adverse events were validated simultaneously.
The Common Terminology Criteria for Adverse Events (PRO-CTCAE) is accurate, reliable.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|